{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-003755","form_type":"8-K","ticker":"TRDA","cik":"0001689375","company_name":"Entrada Therapeutics, Inc.","filed_at":"2025-01-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.451928+00:00","generated_at":"2026-05-28T01:12:16.288988+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Entrada reports ~$420M cash; DMD pipeline advancing with multiple 2025 trial starts","bullets":["Preliminary cash resources ~$420M as of Dec 31, 2024, extending runway into Q2 2027.","Phase 1 ENTR-601-44 data: no treatment-related AEs; dose-dependent PK/PD and statistically significant exon skipping at 6 mg/kg.","Plans to initiate Phase 1/2 MAD studies for ENTR-601-44, -45, -50, and -51 in 2025; Vertex advancing VX-670 MAD portion in DM1.","Preclinical data show dose-dependent dystrophin restoration and functional correction in DMD mouse models across franchise.","Cash and clinical updates based on preliminary unaudited estimates; year-end audit ongoing."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-003755","json":"https://secwatch.observer/filing/0001104659-25-003755.json","markdown":"https://secwatch.observer/filing/0001104659-25-003755.md","text":"https://secwatch.observer/filing/0001104659-25-003755.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1689375/000110465925003755/0001104659-25-003755-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1689375/000110465925003755/tm253290d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T01:12:16.288988+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}